Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma

Amit Mahipal, Mary J. McDonald, Agnieszka Witkiewicz, Brian I. Carr

Research output: Contribution to journalArticle

Abstract

The significance of over-expression of epidermal growth factor receptor (EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association between EGFR over-expression (membranous and cytoplasmic), the associated histopathologic features and clinical outcomes in post-resection pancreatic cancer patients. EGFR expression was determined immunohistochemically in 90 patients who underwent resection for pancreatic cancer. Cytoplasmic expression was considered positive if EGFR expression was seen in the cytoplasm in C10% of cells. Cell membrane staining was scored from 0 to 3?, with 2? and 3? being considered as membrane over-expression. Overall survival and progression-free survival were calculated using the Kaplan-Meiermethod, and survival curveswere compared by the log-rank test. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and cytoplasmic EGFR over-expression, respectively. There was a statistically significant correlation between cell membrane EGFR over-expression and lymph node positivity (P = 0.03). Patients with membrane EGFR over-expression had a shorter median progression-free survival (10.7 vs. 17.0 months, P = 0.02) and overall survival (15.9 months vs. 25.3 months, P = 0.17). Cytoplasmic EFGR over-expression was not significantly associated with recurrence or survival. Membrane EGFR over-expression in resected pancreatic cancer patients was associatedwithworse clinical outcomes than non-over-expression.

Original languageEnglish
Pages (from-to)134-139
Number of pages6
JournalMedical Oncology
Volume29
Issue number1
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Epidermal Growth Factor Receptor
Adenocarcinoma
Cell Membrane
Pancreatic Neoplasms
Survival
Disease-Free Survival
Membranes
Cytoplasm
Lymph Nodes
Staining and Labeling
Recurrence

Keywords

  • EGF receptor
  • Invasion
  • Pancreatic cancer
  • Prognosis
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. / Mahipal, Amit; McDonald, Mary J.; Witkiewicz, Agnieszka; Carr, Brian I.

In: Medical Oncology, Vol. 29, No. 1, 03.2012, p. 134-139.

Research output: Contribution to journalArticle

Mahipal, Amit ; McDonald, Mary J. ; Witkiewicz, Agnieszka ; Carr, Brian I. / Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. In: Medical Oncology. 2012 ; Vol. 29, No. 1. pp. 134-139.
@article{032cff61925e45b29dcf79e29b51a443,
title = "Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma",
abstract = "The significance of over-expression of epidermal growth factor receptor (EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association between EGFR over-expression (membranous and cytoplasmic), the associated histopathologic features and clinical outcomes in post-resection pancreatic cancer patients. EGFR expression was determined immunohistochemically in 90 patients who underwent resection for pancreatic cancer. Cytoplasmic expression was considered positive if EGFR expression was seen in the cytoplasm in C10{\%} of cells. Cell membrane staining was scored from 0 to 3?, with 2? and 3? being considered as membrane over-expression. Overall survival and progression-free survival were calculated using the Kaplan-Meiermethod, and survival curveswere compared by the log-rank test. Out of 90 patients, 51 (57{\%}) and 74 (68{\%}) patients had membrane and cytoplasmic EGFR over-expression, respectively. There was a statistically significant correlation between cell membrane EGFR over-expression and lymph node positivity (P = 0.03). Patients with membrane EGFR over-expression had a shorter median progression-free survival (10.7 vs. 17.0 months, P = 0.02) and overall survival (15.9 months vs. 25.3 months, P = 0.17). Cytoplasmic EFGR over-expression was not significantly associated with recurrence or survival. Membrane EGFR over-expression in resected pancreatic cancer patients was associatedwithworse clinical outcomes than non-over-expression.",
keywords = "EGF receptor, Invasion, Pancreatic cancer, Prognosis, Recurrence",
author = "Amit Mahipal and McDonald, {Mary J.} and Agnieszka Witkiewicz and Carr, {Brian I.}",
year = "2012",
month = "3",
doi = "10.1007/s12032-010-9802-y",
language = "English",
volume = "29",
pages = "134--139",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma

AU - Mahipal, Amit

AU - McDonald, Mary J.

AU - Witkiewicz, Agnieszka

AU - Carr, Brian I.

PY - 2012/3

Y1 - 2012/3

N2 - The significance of over-expression of epidermal growth factor receptor (EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association between EGFR over-expression (membranous and cytoplasmic), the associated histopathologic features and clinical outcomes in post-resection pancreatic cancer patients. EGFR expression was determined immunohistochemically in 90 patients who underwent resection for pancreatic cancer. Cytoplasmic expression was considered positive if EGFR expression was seen in the cytoplasm in C10% of cells. Cell membrane staining was scored from 0 to 3?, with 2? and 3? being considered as membrane over-expression. Overall survival and progression-free survival were calculated using the Kaplan-Meiermethod, and survival curveswere compared by the log-rank test. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and cytoplasmic EGFR over-expression, respectively. There was a statistically significant correlation between cell membrane EGFR over-expression and lymph node positivity (P = 0.03). Patients with membrane EGFR over-expression had a shorter median progression-free survival (10.7 vs. 17.0 months, P = 0.02) and overall survival (15.9 months vs. 25.3 months, P = 0.17). Cytoplasmic EFGR over-expression was not significantly associated with recurrence or survival. Membrane EGFR over-expression in resected pancreatic cancer patients was associatedwithworse clinical outcomes than non-over-expression.

AB - The significance of over-expression of epidermal growth factor receptor (EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association between EGFR over-expression (membranous and cytoplasmic), the associated histopathologic features and clinical outcomes in post-resection pancreatic cancer patients. EGFR expression was determined immunohistochemically in 90 patients who underwent resection for pancreatic cancer. Cytoplasmic expression was considered positive if EGFR expression was seen in the cytoplasm in C10% of cells. Cell membrane staining was scored from 0 to 3?, with 2? and 3? being considered as membrane over-expression. Overall survival and progression-free survival were calculated using the Kaplan-Meiermethod, and survival curveswere compared by the log-rank test. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and cytoplasmic EGFR over-expression, respectively. There was a statistically significant correlation between cell membrane EGFR over-expression and lymph node positivity (P = 0.03). Patients with membrane EGFR over-expression had a shorter median progression-free survival (10.7 vs. 17.0 months, P = 0.02) and overall survival (15.9 months vs. 25.3 months, P = 0.17). Cytoplasmic EFGR over-expression was not significantly associated with recurrence or survival. Membrane EGFR over-expression in resected pancreatic cancer patients was associatedwithworse clinical outcomes than non-over-expression.

KW - EGF receptor

KW - Invasion

KW - Pancreatic cancer

KW - Prognosis

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84864052249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864052249&partnerID=8YFLogxK

U2 - 10.1007/s12032-010-9802-y

DO - 10.1007/s12032-010-9802-y

M3 - Article

C2 - 21264542

AN - SCOPUS:84864052249

VL - 29

SP - 134

EP - 139

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

ER -